InMed Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
InMed Pharmaceuticals has a total shareholder equity of $12.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.3M and $2.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$9.58m |
| Equity | US$12.77m |
| Total liabilities | US$2.48m |
| Total assets | US$15.26m |
Recent financial health updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02InMed's INM-755 CBN cream did not introduce any delay in normal wound healing
Jan 08Financial Position Analysis
Short Term Liabilities: INM's short term assets ($11.8M) exceed its short term liabilities ($1.7M).
Long Term Liabilities: INM's short term assets ($11.8M) exceed its long term liabilities ($802.8K).
Debt to Equity History and Analysis
Debt Level: INM is debt free.
Reducing Debt: INM had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INM has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 16.3% each year.